- What antithrombotic treatment is required in a patient after TAVI in the year 2021?2021 | Third Faculty of Medicine
- The DAPT trial: 12 or 30 months of dual antiplatelet therapy after implantation of drug-eluting stent2016 | First Faculty of Medicine
- Acetylsalicylic acid in primary prevention - new data2019 | Publication without faculty affiliation
- What is the most important for patients with familial hypercholesterolaemia? MedPed project in the Czech and Slovak Republic2016 | First Faculty of Medicine
- Large artery stenoses - management2005 | First Faculty of Medicine
- Peroral antiplatelet treatment of patients with acute coronary syndrome2014 | Third Faculty of Medicine
- 12 months of DAPT after acute coronary syndrome still beats 6 months2018 | Third Faculty of Medicine
- Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial2016 | Publication without faculty affiliation
- Choosing patients for NOAC treatment: what to take into account?2015 | Third Faculty of Medicine, First Faculty of Medicine
- Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study2017 | Third Faculty of Medicine
- RE-DUAL PCI trial - percutaneous coronary intervention in patient with atrial fibrillation treated with dabigatran2018 | Publication without faculty affiliation
- Is it time to replace acetylsalicylic acid monotherapy in secondary prevention with a more effective treatment?2022 | Third Faculty of Medicine
- Apixaban2014 | First Faculty of Medicine
- Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries2016 | Third Faculty of Medicine
- Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry2023 | Publication without faculty affiliation
- Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome2015 | Publication without faculty affiliation
- Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial2009 | Third Faculty of Medicine
- Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel2015 | Third Faculty of Medicine